3,134 publications from this institution
A detailed electron microscopy analysis is reported on the structure of silver nanoprisms synthesized by controlled photoinduced aggregation of Ag nanoparticles. Bending of the nanoprism (111) face is directly revealed in the presence of fringes in both bright and dark field TEM images, which are unequivocally assigned to bending contours. Such contours can be individually imaged through shifting of the objective aperture and selectively allowing transmission of the corresponding diffraction spot. The assignment of a bent structure is supported by images of the lateral sides of the prisms, and high-resolution images where apparent changes in the lattice constant are observed.
The evaluation of predictable variability in blood pressure (BP) and heart rate (HR) by the use of ambulatory devices, and the proper processing of the time series thus obtained, can be useful for the early assessment of hypertensive complications in pregnancy. The authors have used this approach to analyze 759 series of BP and HR sampled by ambulatory monitoring for about 48 hours every four weeks after the first obstetric visit in 71 women with uncomplicated pregnancies and 42 women with gestational hypertension or preeclampsia. The pattern of variation along gestation of the 24-hour mean of BP for each group of pregnant women was established by polynomial regression analysis. This method revealed a BP predictable pattern of variation with gestational age: for normotensive pregnant women, results indicate a steady decrease in BP up to the 21st week of pregnancy, followed by an increase in BP up to the day of delivery. In pregnancies complicated with gestational hypertension or preeclampsia, the 24-hour mean of BP is stable until the 22nd week of pregnancy, and then correlated with gestational age indicating a significant linear increase of BP in the second half of pregnancy. These differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia.
Currently recommended ambulatory blood pressure (BP) monitoring (ABPM) thresholds for diagnosis of hypertension do not differentiate, as international guidelines do for clinic BP, uncomplicated persons at low risk from those at higher risk, e.g., patients with diabetes, for target injury and cardiovascular disease (CVD) risk. We aimed to derive diagnostic thresholds for the awake and asleep systolic (SBP) and diastolic (DBP) BP means based upon CVD outcomes (death from all causes, myocardial infarction, angina pectoris, coronary revascularization, heart failure, acute arterial occlusion of the lower extremities, thrombotic occlusion of the retinal artery, hemorrhagic stroke, ischemic stroke, and transient ischemic attack) for patients with and without diabetes. We prospectively studied 3344 subjects (1718 men/1626 women), 52.6 ± 14.5 (mean ± SD) yrs of age, 607 with type 2 diabetes, during a median follow-up of 5.6 yrs. Those with hypertension at baseline were randomized to ingest all their prescribed hypertension medications upon awakening or the entire daily dose of ≥1 of them at bedtime. At baseline, BP was measured at 20-min intervals from 07:00 to 23:00 h and at 30-min intervals at night for 48 h, and physical activity was simultaneously monitored every minute by wrist actigraphy to accurately derive the awake and asleep BP means. Identical assessment was scheduled annually and more frequently (quarterly) if treatment adjustment was required. Cox regression analysis was used to derive outcome-based reference thresholds for ABPM in subjects with and without diabetes. CVD risk was consistently greater in patients with than without diabetes for awake SBP/DBP means ≥130/75 mm Hg and asleep means ≥110/65 mm Hg. Derived outcome-based reference thresholds for persons without diabetes were 135/85 mm Hg for the awake and 120/70 mm Hg for the asleep SBP/DBP means. In terms of CVD outcome, the equivalent cutoff threshold values for patients with diabetes were 120/75 mm Hg for the awake and 105/60 mm Hg for the asleep SBP/DBP means. Outcome-based reference thresholds for the diagnosis of hypertension were 15/10 mm Hg lower for ambulatory SBP/DBP in patients with than without diabetes. This marked difference indicates the need for revision of current guidelines that propose diagnostic thresholds for ambulatory BP without differentiation between the presence/absence of diabetes.
The discovery of bioactive molecules from botanical sources is an expanding field, preferentially oriented to plants having a tradition of use in medicine and providing high yields and availability. Temperate forage legumes are Fabaceae species that include worldwide-important crops. These plants possess therapeutic virtues that have not only been used in veterinary and folk medicine, but have also attracted the interest of official medicine. We have examined here Medicago sativa (alfalfa), Trifolium pratense and T. repens (clovers), Melilotus albus and M. officinalis (sweet clovers), Lotus corniculatus (birdsfoot trefoil), Onobrychis viciifolia (sainfoin), Lespedeza capitata (roundhead lespedeza), and Galega officinalis (goat's rue). The phytochemical complexes of these species contain secondary metabolites whose pharmacological potentials deserve investigation. Major classes of compounds include alkaloids and amines, cyanogenic glycosides, flavonoids, coumarins, condensed tannins, and saponins. Some of these phytochemicals have been related to antihypercholesterolemia, antidiabetic, antimenopause, anti-inflammatory, antiedema, anthelmintic, and kidney protective effects. Two widely prescribed drugs have been developed starting from temperate forage legumes, namely, the antithrombotic warfarin, inspired from sweet clover's coumarin, and the antidiabetic metformin, a derivative of sainfoin's guanidine. Available evidence suggests that temperate forage legumes are a potentially important resource for the extraction of active principles to be used as nutraceuticals and pharmaceuticals.
PartitionTest test suite
A full-length cDNA encoding glutamate decarboxylase (designated as OsGAD3), which catalyzes the conversion of glutamate to gamma-aminobutyric acid (GABA), was isolated from the GABA-rich giant-embryo Oryza sativa (Shangshi Jing 315). The full-length cDNA of OsGAD3 (SSJ315) has a 1479 bp open reading frame (ORF) encoding a protein of 492 amino acid residues. The deduced protein had an isoelectric point (pI) of 5.72 and a calculated molecular weight of 56.1 kD. Sequence comparison showed that OsGAD3 (SSJ315) matches the glutamate decarboxylases of other plant species reported previously. Analysis of the structural features of the C-terminal portions of plant GADs revealed that OsGAD3 (SSJ315) has the typical CaM-binding domain (CaMBD) in the C-terminal region as most other plant GADs. Evolution analysis showed that plant GADs are conserved in the process of evolution. The cloning and characterization of the OsGAD3 (SSJ315) gene will enable us to use OsGAD3 to enhance GABA production in O. sativa (SSJ315) by metabolic engineering in the near future.
Janus surfaces present technological opportunities both for research and industry in which different chemical, physical and/or structural components need to coexist for a single purpose such as chemistry, textile and material science. Varying inorganic and organic (polymer‐based) materials are conventionally used however, utilizing nature‐derived polymers to fabricate Janus structures is a recent and attractive trend which makes them more applicable for bio‐based treatments with environmental concerns. Particularly, promising applications of Janus structures as being surfactants, drug delivery and micro/nano encapsulation vehicles for biomedical purposes successfully forward the interest on Janus concept to the food related practices. Producing Janus structures from nature‐derived and food grade polymers such as alginate, cellulose, chitosan, lipid nanocrystals, zein and some plant‐proteins and their usage stronger emulsions with higher stabilities, biosensing or antimicrobial practices as well as bioactive delivery and release control might be considered as a new era for food processing industry.
